We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Quo vadis, biological treatment for psoriasis and psoriatic arthritis?
- Authors
Olszewska, Barbara; Adamski, Zygmunt; Czarnecka-Operacz, Magdalena
- Abstract
Psoriasis is a chronic autoimmune disease that affects approximately 2-3% of the world's population. Although the cutaneous manifestations of the disease are the most prevalent, psoriasis is also associated with a systemic inflammation and various co-morbidities linked with autoinflammatory processes. One of those processes is psoriatic arthritis, an inflammatory, seronegative spondyloarthropathy that develops in 13.8-30% of psoriatic patients at some point of their lives. Over the past 15 years the therapeutic options for severe and generalized psoriasis have broadened immensely with the introduction of biological agents to everyday practice. We present a quick overview of current biological therapies in the treatment of psoriasis and prospects for forthcoming advancements in biological treatment.
- Subjects
PSORIATIC arthritis; PSORIASIS; INFLAMMATION; SPONDYLOARTHROPATHIES; COMORBIDITY; PATIENTS; THERAPEUTICS
- Publication
Advances in Dermatology & Allergology / Postępy Dermatologii i Alergologii, 2018, Vol 35, Issue 3, p231
- ISSN
1642-395X
- Publication type
Article
- DOI
10.5114/ada.2018.76086